Cargando…
Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system
BACKGROUND: Immune checkpoint inhibitors (ICIs) and bevacizumab-based therapy are a promising treatment approach to significantly improving overall survival (OS) of non-small cell lung cancer (NSCLC) patients. However, the incidence of adverse events induced by a combination treatment with programme...
Autores principales: | Bai, Shuai, Tian, Tiantian, Pacheco, Jose M., Tachihara, Motoko, Hu, Pingping, Zhang, Jiandong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264309/ https://www.ncbi.nlm.nih.gov/pubmed/34295666 http://dx.doi.org/10.21037/tlcr-21-464 |
Ejemplares similares
-
Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy
por: Huang, Xinyi, et al.
Publicado: (2021) -
Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022) -
Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018) -
Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023) -
Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)